CRISPR Therapeutics
30-Second Executive Brief
Executive Assessment
CRISPR Therapeutics functions as an established institution within Healthcare & Life Sciences, backed by 65% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 65% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 65%
- Ecosystem Influence
- High
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
CRISPR Therapeutics, co-developer with Vertex Pharmaceuticals of Casgevy -- the first FDA-approved CRISPR gene-editing therapy -- reported Q1 2026 Casgevy revenue of $43 million, with the companies projecting revenue to nearly triple over 2026 on expanding patient access, rising infusion volumes, and broader insurance coverage. The company held $2.44 billion in cash as of March 2026 (up from $1.98 billion at year-end, partly from a $585 million convertible note raise) and is advancing a diversified pipeline spanning in vivo liver editing, siRNA programs, an autoimmune/oncology CAR-T platform (zugo-cel), and regenerative medicine for diabetes, while pursuing first-half 2026 regulatory submissions to expand Casgevy's label to patients aged 5-11.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions Vertex
“Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis.”
SEC 8-K exhibit (0001193125-26-204147) · May 4, 2026
Mentions Vertex
“Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.”
SEC 8-K exhibit (0001193125-26-330644) · Aug 3, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 1 government/SEC filing
- CRISPR Therapeutics IR / PackGene Biotech — CRISPR Therapeutics reports Q1 2026 Casgevy revenue growth, pipeline expansioncompany
- U.S. Securities and Exchange Commission (EDGAR) — CRISPR Therapeutics FY2025 Annual Report (Form 10-K), filed with the SECgovernment
Latest Activity
- NewsSnipping a gene to reduce bad cholesterol for life looks possible - CNNGoogle News — Business
- FilingCRISPR Therapeutics filed an 8-K (items 2.02,9.01)8-K
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding CRISPR Therapeutics — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Casgevy's $43M quarterly revenue against a 'triple in 2026' projection shows the real constraint is infusion capacity, not demand
32% confidenceCRISPR Therapeutics and Vertex project Casgevy revenue to nearly triple in 2026 from a Q1 base of $43 million, with growth explicitly tied to expanding infusion center capacity and insurance coverage rather than patient demand.
This is InsightNodes' own interpretive read: Casgevy's ex vivo treatment process requires specialized infusion centers to harvest, edit, and reinfuse a patient's own cells, which is a fundamentally different bottleneck than typical drug commercial ramps that are constrained by prescriber awareness or reimbursement alone -- this means Casgevy's revenue trajectory is more predictable than a typical launch (capacity additions are plannable) but also structurally capped in the near term regardless of how much patient demand exists, a distinction relevant to modeling both CRISPR Therapeutics' and Vertex's near-term Casgevy revenue.
InsightNodes analysis of CRISPR Therapeutics Q1 2026 results · Aug 14, 2026
CRISPR Therapeutics's Timeline
A sourced, dated history of CRISPR Therapeutics's key moments — founding to present.
2026-Q1 · Casgevy revenue reaches $43M, cash position strengthens to $2.44B
CRISPR Therapeutics reported Q1 2026 Casgevy revenue of $43 million, with Vertex and CRISPR projecting revenue to nearly triple in 2026; cash, equivalents and marketable securities reached $2.44 billion, up from $1.98 billion at year-end, aided by $585.4 million in net proceeds from convertible senior notes.